Tatsuhiro Shibata
YOU?
Author Swipe
View article: Table S1, S3 and S8 from Single-Cell Analysis Reveals a CD4<sup>+</sup> T-cell Cluster That Correlates with PD-1 Blockade Efficacy
Table S1, S3 and S8 from Single-Cell Analysis Reveals a CD4<sup>+</sup> T-cell Cluster That Correlates with PD-1 Blockade Efficacy Open
Supplementary Table 1, 3, 8.
View article: Figure S1,S2,S3,S4,S5,S6,S7,S8,S9 and S10 from Single-Cell Analysis Reveals a CD4<sup>+</sup> T-cell Cluster That Correlates with PD-1 Blockade Efficacy
Figure S1,S2,S3,S4,S5,S6,S7,S8,S9 and S10 from Single-Cell Analysis Reveals a CD4<sup>+</sup> T-cell Cluster That Correlates with PD-1 Blockade Efficacy Open
Supplementary Figures 1-10.
View article: Vericiguat and hypotension in patients with heart failure and reduced ejection fraction: VERIFY-HF registry
Vericiguat and hypotension in patients with heart failure and reduced ejection fraction: VERIFY-HF registry Open
Although hypotension was relatively common soon after starting vericiguat, they were not often associated with drug discontinuation. Patients experiencing hypotension had a greater risk of HF outcomes, but this would be primarily associate…
View article: Supplementary Figure S10 from EML4–ALK Rearrangement Creates a Distinctive Myeloid Cell–Dominant Immunosuppressive Microenvironment in Lung Cancer
Supplementary Figure S10 from EML4–ALK Rearrangement Creates a Distinctive Myeloid Cell–Dominant Immunosuppressive Microenvironment in Lung Cancer Open
Supplementary Figure S10. IHC staining of macrophages in the tumor treated with alectinib and anti-PD-L1 inhibitor. A
View article: Data from EML4–ALK Rearrangement Creates a Distinctive Myeloid Cell–Dominant Immunosuppressive Microenvironment in Lung Cancer
Data from EML4–ALK Rearrangement Creates a Distinctive Myeloid Cell–Dominant Immunosuppressive Microenvironment in Lung Cancer Open
Tyrosine kinase inhibitors are initially efficacious against anaplastic lymphoma kinase (ALK) fusion gene–positive lung adenocarcinoma, but acquired resistance inevitably occurs. Therefore, alternative treatment strategies are neede…
View article: Supplementary Figure S11 from EML4–ALK Rearrangement Creates a Distinctive Myeloid Cell–Dominant Immunosuppressive Microenvironment in Lung Cancer
Supplementary Figure S11 from EML4–ALK Rearrangement Creates a Distinctive Myeloid Cell–Dominant Immunosuppressive Microenvironment in Lung Cancer Open
Supplementary Figure S11. IL-6 produced by cancer cells decreases CD8+T cell-attractant chemokine gene expression and induces MDSC.
View article: Supplementary Table S1 from EML4–ALK Rearrangement Creates a Distinctive Myeloid Cell–Dominant Immunosuppressive Microenvironment in Lung Cancer
Supplementary Table S1 from EML4–ALK Rearrangement Creates a Distinctive Myeloid Cell–Dominant Immunosuppressive Microenvironment in Lung Cancer Open
Table S1
View article: Supplementary Figure S2 from EML4–ALK Rearrangement Creates a Distinctive Myeloid Cell–Dominant Immunosuppressive Microenvironment in Lung Cancer
Supplementary Figure S2 from EML4–ALK Rearrangement Creates a Distinctive Myeloid Cell–Dominant Immunosuppressive Microenvironment in Lung Cancer Open
Supplementary Figure S2. CD8+ T cell-attractant chemokine gene expression in UMAP plots of single-cell RNA-sequencing analysis.
View article: Supplementary Table S2 from EML4–ALK Rearrangement Creates a Distinctive Myeloid Cell–Dominant Immunosuppressive Microenvironment in Lung Cancer
Supplementary Table S2 from EML4–ALK Rearrangement Creates a Distinctive Myeloid Cell–Dominant Immunosuppressive Microenvironment in Lung Cancer Open
Table S2
View article: Supplementary Figure S12 from EML4–ALK Rearrangement Creates a Distinctive Myeloid Cell–Dominant Immunosuppressive Microenvironment in Lung Cancer
Supplementary Figure S12 from EML4–ALK Rearrangement Creates a Distinctive Myeloid Cell–Dominant Immunosuppressive Microenvironment in Lung Cancer Open
Supplementary Figure S12. EML4-ALK activates the RAS/MAPK/AP-1 signaling pathway.
View article: Supplementary Figure S3 from EML4–ALK Rearrangement Creates a Distinctive Myeloid Cell–Dominant Immunosuppressive Microenvironment in Lung Cancer
Supplementary Figure S3 from EML4–ALK Rearrangement Creates a Distinctive Myeloid Cell–Dominant Immunosuppressive Microenvironment in Lung Cancer Open
Supplementary Figure S3. Method to generate macrophages and the phenotype of the macrophages.
View article: Supplementary Figure S8 from EML4–ALK Rearrangement Creates a Distinctive Myeloid Cell–Dominant Immunosuppressive Microenvironment in Lung Cancer
Supplementary Figure S8 from EML4–ALK Rearrangement Creates a Distinctive Myeloid Cell–Dominant Immunosuppressive Microenvironment in Lung Cancer Open
Supplementary Figure S8. Gating strategies for mouse immune cell types.
View article: Supplementary Figure S5 from EML4–ALK Rearrangement Creates a Distinctive Myeloid Cell–Dominant Immunosuppressive Microenvironment in Lung Cancer
Supplementary Figure S5 from EML4–ALK Rearrangement Creates a Distinctive Myeloid Cell–Dominant Immunosuppressive Microenvironment in Lung Cancer Open
Supplementary Figure S5.MDSC-abundant TME in fusion gene-positive LUAD.
View article: Supplementary Figure S6 from EML4–ALK Rearrangement Creates a Distinctive Myeloid Cell–Dominant Immunosuppressive Microenvironment in Lung Cancer
Supplementary Figure S6 from EML4–ALK Rearrangement Creates a Distinctive Myeloid Cell–Dominant Immunosuppressive Microenvironment in Lung Cancer Open
Supplementary Figure S6. The strategy of MDSC induction by cancer cells.
View article: Supplementary Figure S9 from EML4–ALK Rearrangement Creates a Distinctive Myeloid Cell–Dominant Immunosuppressive Microenvironment in Lung Cancer
Supplementary Figure S9 from EML4–ALK Rearrangement Creates a Distinctive Myeloid Cell–Dominant Immunosuppressive Microenvironment in Lung Cancer Open
Supplementary Figure S9. Immunohistochemical (IHC) staining of PD-1+ and PD-L1+ cells, and macrophages in the tumor.
View article: Supplementary Figure S7 from EML4–ALK Rearrangement Creates a Distinctive Myeloid Cell–Dominant Immunosuppressive Microenvironment in Lung Cancer
Supplementary Figure S7 from EML4–ALK Rearrangement Creates a Distinctive Myeloid Cell–Dominant Immunosuppressive Microenvironment in Lung Cancer Open
Supplementary Figure S7. The suppressive activity of induced MDSC.
View article: Supplementary Figure S4 from EML4–ALK Rearrangement Creates a Distinctive Myeloid Cell–Dominant Immunosuppressive Microenvironment in Lung Cancer
Supplementary Figure S4 from EML4–ALK Rearrangement Creates a Distinctive Myeloid Cell–Dominant Immunosuppressive Microenvironment in Lung Cancer Open
SupplementaryFigureS4.TheexpressionofdendriticcellmarkersandCD8+Tcell-attractantchemokines in macrophages induced by GM-CSF.
View article: Supplementary Figure S1 from EML4–ALK Rearrangement Creates a Distinctive Myeloid Cell–Dominant Immunosuppressive Microenvironment in Lung Cancer
Supplementary Figure S1 from EML4–ALK Rearrangement Creates a Distinctive Myeloid Cell–Dominant Immunosuppressive Microenvironment in Lung Cancer Open
Supplementary Figure S1. Gating strategies for human immune cell types.
View article: Clinical Significance of Extrachromosomal DNA in <i>FGFR2</i> -Amplified Gastric Cancer: Therapeutic Implications From Clinical Experience
Clinical Significance of Extrachromosomal DNA in <i>FGFR2</i> -Amplified Gastric Cancer: Therapeutic Implications From Clinical Experience Open
View article: tugMedi: simulator of cancer-cell evolution for personalized medicine based on the genomic data of patients
tugMedi: simulator of cancer-cell evolution for personalized medicine based on the genomic data of patients Open
Cancer comprehensive genomic profiling tests are increasingly used, but drug response rates remain limited. Simulations forecasting cancer progression could aid targeted therapies; however, existing simulations focus mainly on basic biolog…
View article: Astroblastoma With <scp><i>MN1</i></scp>::<scp><i>BEND2</i></scp> Fusion Showing an Atypical Signal Pattern in <scp><i>MN1</i></scp> Break‐Apart <scp>FISH</scp>: A Potential Diagnostic Pitfall
Astroblastoma With <span><i>MN1</i></span>::<span><i>BEND2</i></span> Fusion Showing an Atypical Signal Pattern in <span><i>MN1</i></span> Break‐Apart <span>FISH</span>: A Potential Diagnostic Pitfall Open
View article: MAGGIC risk score and drug-related adverse events of sacubitril/valsartan: Insights from the REVIEW-HF registry
MAGGIC risk score and drug-related adverse events of sacubitril/valsartan: Insights from the REVIEW-HF registry Open
View article: Geographic and age variations in mutational processes in colorectal cancer
Geographic and age variations in mutational processes in colorectal cancer Open
Incidence rates of colorectal cancer vary geographically and have changed over time 1 . Notably, in the past two decades, the incidence of early-onset colorectal cancer, which affects individuals below 50 years of age, has doubled in many …
View article: Prognostic Impact of Sustained Reduction of N-Terminal Pro-B-Type Natriuretic Peptide After Initiating Sacubitril/Valsartan ― Insights From the REVIEW-HF Registry ―
Prognostic Impact of Sustained Reduction of N-Terminal Pro-B-Type Natriuretic Peptide After Initiating Sacubitril/Valsartan ― Insights From the REVIEW-HF Registry ― Open
Repeated NT-proBNP monitoring and the pattern of the NT-proBNP trajectory after Sac/Val may be helpful in optimizing HF therapy and understanding the prognosis of HF.
View article: Comprehensive analysis of prognosis markers with molecular features derived from pan-cancer whole-genome sequences
Comprehensive analysis of prognosis markers with molecular features derived from pan-cancer whole-genome sequences Open
View article: Geographic and age-related variations in mutational processes in colorectal cancer
Geographic and age-related variations in mutational processes in colorectal cancer Open
Colorectal cancer incidence rates vary geographically and have changed over time. Notably, in the past two decades, the incidence of early-onset colorectal cancer, affecting individuals under the age of 50 years, has doubled in many countr…
View article: Uptitration of Sacubitril/Valsartan and Outcomes in Patients With Heart Failure ― Insight From the REVIEW-HF Registry ―
Uptitration of Sacubitril/Valsartan and Outcomes in Patients With Heart Failure ― Insight From the REVIEW-HF Registry ― Open
Patients who achieved sacubitril/valsartan uptitration had a better prognosis than those who did not. Before sacubitril/valsartan uptitration, patients need to monitor blood pressure closely to prevent worsening events.
View article: Risk stratification by renal function and NYHA class in patients with hypotension initiated on sacubitril/valsartan: a retrospective cohort study from 17 centres in Japan
Risk stratification by renal function and NYHA class in patients with hypotension initiated on sacubitril/valsartan: a retrospective cohort study from 17 centres in Japan Open
Background Patients with heart failure exhibiting low systolic blood pressure (SBP) have a poor prognosis. Sacubitril/valsartan reduces cardiovascular events; however, its use in patients with low SBP has not been fully examined. Therefore…
View article: Microbiome spectra and prevalent colibactin-associated mutational process in Japanese colorectal cancer
Microbiome spectra and prevalent colibactin-associated mutational process in Japanese colorectal cancer Open
The recent rapid increase in colorectal cancer (CRC) cases, particularly among young patients, poses a significant public health concern in Japan and other countries. The association between the gut microbiota and CRC has been well establi…
View article: Geographic variation of mutagenic exposures in kidney cancer genomes
Geographic variation of mutagenic exposures in kidney cancer genomes Open